Is Ribociclib on the market?

Ribociclib (Ribociclib) was approved by the US Food and Drug Administration (FDA) in March 2017 and the European Medicines Agency (EMA) in August 2017 under the trade name Kisqali. It was approved for use in the National Health Service (NHS) by the National Institute for Health and Care Excellence (NICE) in February 2021. The original drug of Riboxil was approved by the National Medical Products Administration and launched in China in 2013 under the trade name Kaililong.

Reboxiclib is an oral tablet that can be used in combination with an aromatase inhibitor or fulvestrant to increase the time to progression in patients with HR-positive and HER2-negative locally advanced or metastatic breast cancer. When reboxiclib was combined with aromatase inhibitors and drugs that block LHRH, premenopausal and perimenopausal women with advanced breast cancer also lived longer without their cancer getting worse. Riboxiclib's side effect pattern is well established, with the most common side effects being infection, low white blood cell levels, headache, cough, nausea, vomiting, diarrhea, constipation, fatigue, hair loss, and rash, which can be managed.

After the original drug Riboxil was launched in China, due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.